Halaven eribulin mesylate regulatory update

Eisai said NHS England removed breast cancer drug Halaven eribulin mesylate from the Cancer Drugs Fund (CDF), making it the first

Read the full 216 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE